CGIM
KNSA icon

Cannon Global Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cannon Global Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,000
Closed -$530K – 72
2026
Q1 		$530K Buy
+11,000
New +$487K 1.03% 32
2025
Q3 		– Sell
-17,300
Closed -$479K – 81
2025
Q2 		$479K Buy
+17,300
New +$440K 0.98% 33

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Cannon Global Investment Management's KNSA Position: Q2 2026 in Review

Cannon Global Investment Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 11,000 shares — an estimated $530K sold.

Cannon Global Investment Management first reported a position in KNSA in Q2 2025 and held it in 2 quarters. The position peaked at $530K in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Cannon Global Investment Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cannon Global Investment Management sold 11,000 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $530K.
  • Cannon Global Investment Management first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Cannon Global Investment Management's Kiniksa Pharmaceuticals position peaked at $530K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.